Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Virion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    89 result(s) found for: Virion. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2014-000785-21 Sponsor Protocol Number: GQM11 Start Date*: 2014-07-24
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects
    Medical condition: Prevention of influenza infection in adults from 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000629-19 Sponsor Protocol Number: GID47 Start Date*: 2014-08-21
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety assessment of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2014-2015 Formulation (Intradermal Route)
    Medical condition: Prophylaxis of influenza (2014-2015 Northern Hemisphere Season)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005101-79 Sponsor Protocol Number: GQM04 Start Date*: 2012-10-05
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Child/Adolescent and Adult Subjects
    Medical condition: Prophylaxis of influenza in subjects from 9-17 years of age (and adults aged 18 to 60 years).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005243-25 Sponsor Protocol Number: GID37 Start Date*: 2013-04-16
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route)
    Medical condition: Prophylaxis of influenza (2013-2014 Northern Hemisphere Season)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004763-40 Sponsor Protocol Number: GQM14 Start Date*: 2017-04-05
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) in Pregnant Women
    Medical condition: Prophylaxix of influenza in Pregnant Women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-005374-33 Sponsor Protocol Number: GQM02 Start Date*: 2013-06-06
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety and Immunogenicity of the Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Children Aged 3 to 8 Years
    Medical condition: Prophylaxis of influenza in children aged 3 to 8 years
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-001231-51 Sponsor Protocol Number: GQM05 Start Date*: 2014-05-20
    Sponsor Name:Sanofi Pasteur
    Full Title: Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 Months
    Medical condition: Prevention of influenza infection in children aged 6 to 35 months
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-002369-37 Sponsor Protocol Number: GID23 Start Date*: 2006-09-25
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Lot-to-Lot Consistency Study of the Investigational, Split-virion, Inactivated Influenza Vaccine, Administered by the Intradermal Route in Adults.
    Medical condition: Vaccination of adults aged 18 to 60 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000671-15 Sponsor Protocol Number: GRT63 Start Date*: 2006-05-04
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)
    Medical condition: Vaccination of healthy subjects aged 18 to 60 years (60 subjects) and over the 60 years (60 subjects) with one dose of the new formulation of the influenza vaccine for the 2006-2007 Northern Hemisp...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000943-33 Sponsor Protocol Number: GRT83 Start Date*: 2008-04-23
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)
    Medical condition: Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002965-35 Sponsor Protocol Number: GID18 Start Date*: 2005-09-15
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children
    Medical condition: Vaccination of healthy children aged 6 to 35 months and 3 to 8 years (2 doses at a 28 day-interval)
    Disease: Version SOC Term Classification Code Term Level
    10036897
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-017690-38 Sponsor Protocol Number: GRT90 Start Date*: 2010-04-06
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)
    Medical condition: Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004164-23 Sponsor Protocol Number: 710501 Start Date*: 2006-01-09
    Sponsor Name:Baxter AG
    Full Title: Single-blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero cell derived) with a Licensed Egg derived Infl...
    Medical condition: Influenza Vaccination in healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018991-25 Sponsor Protocol Number: GPF18 Start Date*: 2010-03-15
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects
    Medical condition: Preventive vaccination in healthy subjects aged 18 to 60 years against infection with S-OIV (Swine Origin Influenza Virus) A/California/7/2009 (H1N1)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000101-54 Sponsor Protocol Number: 8162 Start Date*: 2006-02-10
    Sponsor Name:University Hospitals Leicester, Leicester General Hospital
    Full Title: A randomized, observer-blind, dose-ranging, single-centre, study to evaluate the safety, tolerability and immunogenicity of adjuvanted and non-adjuvanted influenza A/Hong Kong/1073/99 (H9N2) vaccin...
    Medical condition: Vaccine study to assess the safety and immunogenicity of whole virus, alum-adjuvanted whole virus and virosomal A/HongKong/1073/99 (H9N2) vaccine in healthy adult volunteers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017688-40 Sponsor Protocol Number: GID34 Start Date*: 2010-04-16
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)
    Medical condition: Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intraderma route
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009977-85 Sponsor Protocol Number: GID29 Start Date*: 2009-05-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)
    Medical condition: Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intradermal route
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001219-39 Sponsor Protocol Number: GID24 Start Date*: 2008-06-20
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxig...
    Medical condition: Vaccination of adults subjects aged 50 to 59 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001374-34 Sponsor Protocol Number: 231 Start Date*: 2005-01-03
    Sponsor Name:Baxter Vaccine AG
    Full Title: SINGLE-BLIND RANDOMIZED CONTROLLED PHASE II/III STUDY TO INVESTIGATE THE IMMUNOGENICITY AND SAFETY AFTER A SINGLE VACCINATION WITH ONE OF THREE DIFFERENT LOTS OF AN INACTIVATED INFLUENZA VACCINE (W...
    Medical condition: Influenza Vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-005026-39 Sponsor Protocol Number: QHD04 Start Date*: 2019-02-01
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 months to 17 Years of Age
    Medical condition: Prevention of influenza infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 15:03:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA